Boston Scientific Corporation To Adopt HRS Guidelines
NATICK, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that it plans to adopt the recommendations announced today by the Heart Rhythm Society (HRS) Task Force on medical device performance policies and guidelines. The Company issued the following statement:
"Boston Scientific continues to support and commend the Heart Rhythm Society (HRS) for the development of guidelines regarding device performance. We continue to believe these guidelines are in the best interest of patients and physicians, and we plan to adopt them.
We plan to implement additional changes consistent with HRS guidelines, continuing our commitment to best facilitate patient care with safe and reliable therapy. This includes our commitment to the development of independent, industry-wide oversight to facilitate consistent communications, surveillance and product performance reporting practices.
Boston Scientific CRM has implemented industry-leading systems and practices consistent with the guidelines, for example:
* The industry-leading Boston Scientific CRM Product Performance Report clearly demonstrates our commitment to timely and responsible communication. The CRM Product Performance Report (PPR) is published quarterly. Our monthly CRM Product News supplements the quarterly PPR, highlighting information related to our products and therapies. Both the CRM Product Performance Report and the CRM Product News can be easily accessed either by subscription or online at http://www.guidant.com. * Boston Scientific's LATITUDE(R) Patient Management System is the only wireless and remote patient management system that meets both Heart Rhythm Society Guidelines for automatic device surveillance and American College of Cardiology/American Heart Association Guidelines for monitoring weight, activities of daily living and blood pressure."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation Boston Scientific Corporation
CONTACT: Milan Kofol of Investor Relations, +1-508-650-8569, or PaulDonovan, Media Relations, +1-508-650-8541, both of Boston ScientificCorporation
Web site: http://www.bostonscientific.com/